# ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

> **NCT00508430** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 199 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** ASP8825
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00508430
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 199 (ACTUAL)
- **Why stopped:** An independent DMC determined continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo on the primary endpoint
- **Last updated:** 2008-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508430, "ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00508430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*